Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Genetic Addiction Risk Score (GARS): molecular neurogenetic evidence for predisposition to Reward Deficiency Syndrome (RDS).

Blum K, Oscar-Berman M, Demetrovics Z, Barh D, Gold MS.

Mol Neurobiol. 2014 Dec;50(3):765-96. doi: 10.1007/s12035-014-8726-5. Epub 2014 May 31.

2.

Neurogenetic Impairments of Brain Reward Circuitry Links to Reward Deficiency Syndrome (RDS): Potential Nutrigenomic Induced Dopaminergic Activation.

Blum K, Oscar-Berman M, Giordano J, Downs B, Simpatico T, Han D, Femino J.

J Genet Syndr Gene Ther. 2012 Oct 17;3(4). pii: 1000e115.

3.

Dopamine Genetics and Function in Food and Substance Abuse.

Blum K, Oscar-Berman M, Barh D, Giordano J, Gold M.

J Genet Syndr Gene Ther. 2013 Feb 10;4(121). pii: 1000121.

4.

Coupling Neurogenetics (GARS™) and a Nutrigenomic Based Dopaminergic Agonist to Treat Reward Deficiency Syndrome (RDS): Targeting Polymorphic Reward Genes for Carbohydrate Addiction Algorithms.

Blum K, Simpatico T, Badgaiyan RD, Demetrovics Z, Fratantonio J, Agan G, Febo M, Gold MS.

J Reward Defic Syndr. 2015;1(2):75-80. Epub 2015 Jun 24.

5.

Manipulation of catechol-O-methyl-transferase (COMT) activity to influence the attenuation of substance seeking behavior, a subtype of Reward Deficiency Syndrome (RDS), is dependent upon gene polymorphisms: a hypothesis.

Blum K, Chen TJ, Meshkin B, Waite RL, Downs BW, Blum SH, Mengucci JF, Arcuri V, Braverman ER, Palomo T.

Med Hypotheses. 2007;69(5):1054-60. Epub 2007 Apr 30.

PMID:
17467918
6.

Neurogenetics and clinical evidence for the putative activation of the brain reward circuitry by a neuroadaptagen: proposing an addiction candidate gene panel map.

Chen TJ, Blum K, Chen AL, Bowirrat A, Downs WB, Madigan MA, Waite RL, Bailey JA, Kerner M, Yeldandi S, Majmundar N, Giordano J, Morse S, Miller D, Fornari F, Braverman ER.

J Psychoactive Drugs. 2011 Apr-Jun;43(2):108-27.

PMID:
21858957
7.

Common Neurogenetic Diagnosis and Meso-Limbic Manipulation of Hypodopaminergic Function in Reward Deficiency Syndrome (RDS): Changing the Recovery Landscape.

Blum K, Febo M, Badgaiyan RD, Demetrovics Z, Simpatico T, Fahlke C, M OB, Li M, Dushaj K, Gold MS.

Curr Neuropharmacol. 2017;15(1):184-194. Review.

8.

Neuro-chemical activation of brain reward meso-limbic circuitry is associated with relapse prevention and drug hunger: a hypothesis.

Blum K, Gold MS.

Med Hypotheses. 2011 Apr;76(4):576-84. doi: 10.1016/j.mehy.2011.01.005.

PMID:
21306831
9.

A Shared Molecular and Genetic Basis for Food and Drug Addiction: Overcoming Hypodopaminergic Trait/State by Incorporating Dopamine Agonistic Therapy in Psychiatry.

Gold MS, Badgaiyan RD, Blum K.

Psychiatr Clin North Am. 2015 Sep;38(3):419-62. doi: 10.1016/j.psc.2015.05.011. Review.

PMID:
26300032
10.

Reward deficiency syndrome: genetic aspects of behavioral disorders.

Comings DE, Blum K.

Prog Brain Res. 2000;126:325-41. Review.

PMID:
11105655
11.

Generational association studies of dopaminergic genes in reward deficiency syndrome (RDS) subjects: selecting appropriate phenotypes for reward dependence behaviors.

Blum K, Chen AL, Oscar-Berman M, Chen TJ, Lubar J, White N, Lubar J, Bowirrat A, Braverman E, Schoolfield J, Waite RL, Downs BW, Madigan M, Comings DE, Davis C, Kerner MM, Knopf J, Palomo T, Giordano JJ, Morse SA, Fornari F, Barh D, Femino J, Bailey JA.

Int J Environ Res Public Health. 2011 Dec;8(12):4425-59. doi: 10.3390/ijerph8124425. Epub 2011 Nov 29.

12.

The Benefits of Genetic Addiction Risk Score (GARS) Testing in Substance Use Disorder (SUD).

Blum K, Modestino EJ, Gondre-Lewis M, Chapman EJ, Neary J, Siwicki D, Baron D, Hauser M, Smith DE, Roy AK, Thanos PK, Steinberg B, McLaughlin T, Fried L, Barh D, Dunston GA, Badgaiyan RD.

Int J Genom Data Min. 2018;2018(1). pii: 115. doi: 10.29014/IJGD-115.000015. Epub 2018 Jan 15.

13.

Molecular Genetic Testing in Reward Deficiency Syndrome (RDS): Facts and Fiction.

Blum K, Badgaiyan RD, Agan G, Fratantonio J, Simpatico T, Febo M, Haberstick BC, Smolen A, Gold MS.

J Reward Defic Syndr. 2015;1(1):65-68.

14.

Neurogenetics and gene therapy for reward deficiency syndrome: are we going to the Promised Land?

Blum K, Thanos PK, Badgaiyan RD, Febo M, Oscar-Berman M, Fratantonio J, Demotrovics Z, Gold MS.

Expert Opin Biol Ther. 2015 Jul;15(7):973-85. doi: 10.1517/14712598.2015.1045871. Epub 2015 May 14. Review.

PMID:
25974314
15.

Hypothesizing dopaminergic genetic antecedents in schizophrenia and substance seeking behavior.

Blum K, Oscar-Berman M, Badgaiyan RD, Palomo T, Gold MS.

Med Hypotheses. 2014 May;82(5):606-14. doi: 10.1016/j.mehy.2014.02.019. Epub 2014 Feb 26.

16.

Neurogenetics and Nutrigenomics of Neuro-Nutrient Therapy for Reward Deficiency Syndrome (RDS): Clinical Ramifications as a Function of Molecular Neurobiological Mechanisms.

Blum K, Oscar-Berman M, Stuller E, Miller D, Giordano J, Morse S, McCormick L, Downs WB, Waite RL, Barh D, Neal D, Braverman ER, Lohmann R, Borsten J, Hauser M, Han D, Liu Y, Helman M, Simpatico T.

J Addict Res Ther. 2012 Nov 27;3(5):139.

17.

Hatching the behavioral addiction egg: Reward Deficiency Solution System (RDSS)™ as a function of dopaminergic neurogenetics and brain functional connectivity linking all addictions under a common rubric.

Blum K, Febo M, McLaughlin T, Cronjé FJ, Han D, Gold SM.

J Behav Addict. 2014 Sep;3(3):149-56. doi: 10.1556/JBA.3.2014.019. Epub 2014 Aug 26. Review.

18.

Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors.

Blum K, Braverman ER, Holder JM, Lubar JF, Monastra VJ, Miller D, Lubar JO, Chen TJ, Comings DE.

J Psychoactive Drugs. 2000 Nov;32 Suppl:i-iv, 1-112. Review.

PMID:
11280926
19.

Dopamine homeostasis: brain functional connectivity in reward deficiency syndrome.

Febo M, Blum K, Badgaiyan RD, Baron D, Thanos PK, Colon-Perez LM, Demortrovics Z, Gold MS.

Front Biosci (Landmark Ed). 2017 Jan 1;22:669-691. Review.

PMID:
27814639
20.

Neurogenetics of dopaminergic receptor supersensitivity in activation of brain reward circuitry and relapse: proposing "deprivation-amplification relapse therapy" (DART).

Blum K, Chen TJ, Downs BW, Bowirrat A, Waite RL, Braverman ER, Madigan M, Oscar-Berman M, DiNubile N, Stice E, Giordano J, Morse S, Gold M.

Postgrad Med. 2009 Nov;121(6):176-96. doi: 10.3810/pgm.2009.11.2087. Review.

Supplemental Content

Support Center